GRCE Stock Summary and Trading Ideas (Grace Therapeutics | NASDAQ:GRCE)

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Grace Therapeutics trades on the NASDAQ stock market under the symbol GRCE.

As of March 3, 2026, GRCE stock price declined to $3.93 with 205,926 million shares trading.

GRCE has a beta of 1.51, meaning it tends to be more sensitive to market movements. GRCE has a correlation of 0.22 to the broad based SPY ETF.

GRCE has a market cap of $60.81 million. This is considered a Micro Cap stock.

The top ETF exchange traded funds that GRCE belongs to (by Net Assets): VTI.

GRCE has outperformed the market in the last year with a price return of +29.7% while the SPY ETF gained +15.7%. GRCE has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +25.2% and +8.9%, respectively, while the SPY returned +0.1% and -0.2%, respectively.

GRCE support price is $3.89 and resistance is $4.25 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GRCE shares will trade within this expected range on the day.